Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: A randomized study

Clinical and Experimental Allergy

Volumn 34, Issue 4, 2004, Pages 639-645

  Pacor, M L ^a,c   Di Lorenzo, G ^b   Martinelli, N ^a   Mansueto, P ^b   Rini, G B ^b   Corrocher, R ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Dipartimento di Medicina Clinica e Sperimentale   (Italy)

Author keywords

Atopic dermatitis; Cetirizine; Cyclosporine; SCORAD; Tacrolimus

Indexed keywords

CETIRIZINE; CREATININE; CYCLOSPORIN; CYCLOSPORIN A; TACROLIMUS;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; ATOPIC DERMATITIS; BLOOD ANALYSIS; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART RATE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN BURNING SENSATION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; URINALYSIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CYCLOSPORINE; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EOSINOPHILS; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; OINTMENTS; SEVERITY OF ILLNESS INDEX; TACROLIMUS;

EID: 2042503032     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2004.1907.x     Document Type: Article

References (27)

1. Mihm MC Jr, Soter NA, Dvorak HF, Austen KF. The structure and morphology of normal and atopic eczema. J Invest Dermatol 1976; 67:305-12.
2. + T cells. Immunol Today 1991; 12:392-5.
3. Grewe M, Gyufko K, Schopf E, Krutmann J. Lesional expression of interferon-γ in atopic eczema. Lancet 1994; 343:25-6.
4. Grewe M, Walther S, Gyufko K, Czech W, Schopf E, Krutmann J. Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J Invest Dermatol 1995; 105:407-10.
5. Hamid Q, Boguniewicz M, Leung DYM. Differential in situ cytokine gene expression in acute vs. chronic atopic dermatitis. J Clin Invest 1994; 94:870-6.
6. Yamada N, Wakugawa M, Kuwata S, Yoshida T, Nakagawa H. Chronologic analysis of in situ cytokine expression in mite allergen-induced dermatitis in atopic subjects. J Allergy Clin Immunol 1995; 96:1069-75.
7. Thepen T, Langeveld-Wildschut EG, Bihari IC et al. Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study. J Allergy Clin Immunol 1996; 97:828-37.
8. Larsen FS, Diepgen T, Svensson A. The occurrence of atopic dermatitis in North Europe: an international questionnaire study. J Am Acad Dermatol 1996; 34:760-4.
9. Leung DY. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000; 105:860-76.
10. Simons FE. Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis, ETAC Study Group: early treatment of the atopic child. J Allergy Clin Immunol 1999; 104:433-40.
11. Klein PA, Clark RA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999; 135:1522-5.
12. Geba GP, Ptak W, Askenase PW. Topical tacrolimus and cyclosporine A differentially inhibit early and late effector phases of cutaneous delayed-type and immunoglobulin E hypersensitivity. Immunology 2001; 135:235-42.
13. Salek MS, Finlay AY, Luscombe DK et al. Cyclosporine greatly improves the quality of life of adults with severe atopic dermatitis: a randomized, double blind, placebo-controlled trial. Br J Dermatol 1993; 129:422-30.
14. Camp RD, Reitamo S, Friedmann PS, Ho V, Heule F. Cyclosporine A in severe, therapy-resistant atopic dermatitis: report of an international workshop, April 1993. Br J Dermatol 1993; 129:217-20.
15. Gianni LM, Sulli MM. Topical tacrolimus in the treatment of atopic dermatitis. Ann Pharmacother 2001; 35:943-6.
16. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol (Suppl. Stockh) 1989; 144:13-4.
17. Aoyama H, Tabata N, Tanaka M, Uesugi Y, Tagami K. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment (letter). Br J Dermatol 1995; 133:494-6.
18. Severity scoring of atopic dermatitis: the SCORAD Index. Consensus report of the European Task Force on atopic dermatitis. Dermatology 1993; 86:23-31.
19. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990; 300:230-5.
20. Tofte SJ, Hanifin JM. Current management and therapy of atopic dermatitis. J Am Acad Dermatol 2001; 44 (1 Suppl.): S13-6.
21. Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 2001; 44 (1 Suppl.):S1-12.
22. Bornhovd E, Burgdorf WH, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001; 45:736-43.
23. Hanifin JM, Chan S. Biochemical and immunologic mechanisms in atopic dermatitis: new targets for emerging therapies. J Am Acad Dermatol 1999; 41:72-7.
24. Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium? Arch Dermatol 1999; 135:574-80. Mrowietz U. Macrolide immunosuppressants. Eur J Dermatol 1999; 9:346-51.
25. Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium? Arch Dermatol 1999; 135:574-80. Mrowietz U. Macrolide immunosuppressants. Eur J Dermatol 1999; 9:346-51.
26. Wollenberg A, Bieber T. FK-506/Tacrolimus. In: Burg G, Dummer RG, eds. Strategies for immunointerventions in dermatology. Berlin: Springer, 1997; 53-7.
27. Reitamo S, Rissanen J, Remitz A et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111:396-8.